297 related articles for article (PubMed ID: 26965285)
21. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
[TBL] [Abstract][Full Text] [Related]
22. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.
Chung E; Hsu CL; Kondo M
PLoS One; 2011; 6(12):e28350. PubMed ID: 22164275
[TBL] [Abstract][Full Text] [Related]
23. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
24. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
25. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
26. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
27. PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
Goodwin CB; Li XJ; Mali RS; Chan G; Kang M; Liu Z; Vanhaesebroeck B; Neel BG; Loh ML; Lannutti BJ; Kapur R; Chan RJ
Blood; 2014 May; 123(18):2838-42. PubMed ID: 24553178
[TBL] [Abstract][Full Text] [Related]
28. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
29. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
30. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
31. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
[TBL] [Abstract][Full Text] [Related]
32. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions.
Yang L; Guo W; Zhang Q; Li H; Liu X; Yang Y; Zuo J; Liu W
J Mol Biol; 2011 Dec; 414(5):654-66. PubMed ID: 21964438
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
34. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
36. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
[TBL] [Abstract][Full Text] [Related]
37. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
McCubrey JA; Lee JT; Steelman LS; Blalock WL; Moye PW; Chang F; Pearce M; Shelton JG; White MK; Franklin RA; Pohnert SC
Cancer Detect Prev; 2001; 25(4):375-93. PubMed ID: 11531015
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.
Yellen P; Foster DA
Cancer Lett; 2014 Oct; 353(2):258-63. PubMed ID: 25086185
[TBL] [Abstract][Full Text] [Related]
39. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
40. AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I; Huang Z; Wen Q; Stankiewicz MJ; Gilles L; Goldenson B; Schultz R; Diebold L; Gurbuxani S; Finke CM; Lasho TL; Koppikar P; Pardanani A; Stein B; Altman JK; Levine RL; Tefferi A; Crispino JD
Leukemia; 2013 Sep; 27(9):1882-90. PubMed ID: 23748344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
